Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Fri Jun 25 20:34:19 UTC 2021
by
admin
on
Fri Jun 25 20:34:19 UTC 2021
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
NJ1Q2Q7LO5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
P21554
Created by
admin on Fri Jun 25 20:34:19 UTC 2021 , Edited by admin on Fri Jun 25 20:34:19 UTC 2021
|
PRIMARY | |||
|
P21554
Created by
admin on Fri Jun 25 20:34:19 UTC 2021 , Edited by admin on Fri Jun 25 20:34:19 UTC 2021
|
PRIMARY | |||
|
NJ1Q2Q7LO5
Created by
admin on Fri Jun 25 20:34:19 UTC 2021 , Edited by admin on Fri Jun 25 20:34:19 UTC 2021
|
PRIMARY |
Glycosylation Type | HUMAN |
Glycosylation Link Type | Site |
---|---|
N | 1_77 |
N | 1_83 |
N | 1_112 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
EC50
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET | |||
|
ACTIVATOR -> TARGET | |||
|
AGONIST -> TARGET | |||
|
RADIOLIGAND->TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
||
|
INHIBITOR -> TARGET |
Rimonabant was the first CB1r antagonist to be approved for the treatment of obesity in Europe (Van Gaal et al., 2005; Henness et al., 2006). It was withdrawn from the market in 2008 because it was found to cause a significant drug-related risk of serious psychiatric disorders including anxiety and depression (Christensen et al., 2007).
Ki
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
INVERSE AGONIST->TARGET | |||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
||
|
INVERSE AGONIST->TARGET | |||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
A potent agonist
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
5F-CUMYL-PEGACLONE acts as a potent full agonist of the CB1 receptor.
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
||
|
AGONIST -> TARGET |
ASSUMED ACTIVITY FROM ANALOGS
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Molecular Formula | CHEMICAL |
|
||||
MOL_WEIGHT | CHEMICAL |
|